Ortho · DevicesPhiladelphia, PA (NJ re-domicile under consideration)Returning presenter (Apr 2022)
Round
$5,000,000 Priced Round @ $15M pre-money
Closed
$315K closed, $200K committed, $100K circled
FDA milestone
510(k) — predicate identified; pivotal animal study complete; awaiting clearance
FDA timeline
510(k) submission target late summer/early fall 2026; target clearance Early Spring 2027
Other groups in round
CTAN, Delaware Crossing, Rowan venture fund; in diligence with Rio Grande, Cowtown, Aggie network; DCIG, RIVF
Traction: Pivotal animal study complete; Cretex Medical contract mfg retained; 50+ clinician sites lined up; Plug & Play Accelerator with Zimmer; named strategic acquirer list (8 companies)
What they're looking for: Looking for clinicians AND billing experts regarding image-guided musculoskeletal procedures (orthopedists, interventional radiologists)
After the session
Trace Orthopedics — Medical Mondays, June 22, 2026
Investor sentiment (32 responses):
- High interest: 0
- Medium: 2
- Low: 9
- No interest: 19
Investor engagement:
- Groups invited to apply: 2
- Investors who invited the company to apply: 3
- Investors who requested a 1:1 connection: 1
Summary: A single-use percutaneous tendon-fastener system for partial tendon tears, now a C-corporation, presented its $5M B round. The room viewed the technology favorably and as differentiated, while feedback centered on return scale and the path to a meaningful exit. Two groups invited the company to apply.
Dental · TherapeuticssAtlanta/Georgia
Round
$2,500,000 Convertible Note @ $9,000,000 | 20% discount
Closed
$750,000 committed
FDA milestone
pre-IND meeting
FDA timeline
IND submission Q2 2027, NDA Q4 2028
Other groups in round
Atlanta Tech Angels, Georgia Research Alliance, three independent family offices
Traction: ICORP customer discovery completed
What they're looking for: We welcome advisors in regulatory and hospital reimbursement
After the session
Oridivus Inc. — Medical Mondays, June 22, 2026
Investor sentiment (27 responses):
- High interest: 4
- Medium: 6
- Low: 6
- No interest: 9
Investor engagement:
- Groups invited to apply: 4
- Investors who invited the company to apply: 5
- Investors who requested a 1:1 connection: 1
Summary: A first-in-class electrospun therapeutic membrane for oral mucosal wound healing presented its $2.5M seed round, led by Johnson Venture Partners. The room engaged strongly, with clear champions citing team quality and the lack of a standard of care; the central discussion centered on the product's regulatory classification (drug vs. device / 505(b)(2)) and IP scope. Five investors across four groups invited the company to apply.
Cardio · DevicesIrvine / CA
Round
$4,000,000 Priced Round @ $15,000,000 pre money
Closed
$1M signed term sheet (MicroPort Scientific) + ~$1M soft-circled (Duke Capital Partners, 1918 Ventures/Hopkins fund); $2M remaining of the $4M round. Total capital to date $1.3M ($550K dilutive + $750K non-dilutive)
FDA milestone
multiple pre-submissions, 513g confirming 510(k) pathway
FDA timeline
510(k) submission expected by end of 2026
Other groups in round
1918 angels, Duke Capital Partners, Hamamatsu
Traction: LOI signed from largest ECPR center in the world, 6 first customers identified; BARDA follow-on $10.5M pending (BARDA waiting on available cash); NIH SBIR $600K confirmed
What they're looking for: looking for commercialization advisors and customer introductions
After the session
InFlo Medical — Medical Mondays, June 22, 2026
Investor sentiment (26 responses):
- High interest: 2
- Medium: 15
- Low: 3
- No interest: 5
Investor engagement:
- Groups invited to apply: 8
- Investors who invited the company to apply: 9
- Investors who requested a 1:1 connection: 3
Summary: A briefcase-sized, simplified ECMO system for cardiac-arrest resuscitation drew the strongest response of the day. The clinical voices in the room engaged constructively on best-in-class oxygenator/pump performance, cost, and reduced training, while the central discussion focused on market size and whether hospitals adopt it as a true replacement for traditional ECMO. Nine investors across eight groups invited the company to apply, and a strategic partner (MicroPort Scientific) leads the round with a signed LOI.
